Time on boards
- Boards served
- 4
- Current seats
- 4
- Board service
- 14 years
- Director since
- 2023
14 years of board service in total across 4 boards, counting each seat separately. Longest: Eledon Pharmaceuticals Inc., 3 years.
Eledon Pharmaceuticals Inc.
Director
Neurocrine Biosciences Inc.
Director
Travere Therapeutics Inc.
Director
Rigel Pharmaceuticals Inc.
Director
Insider trades
All notable trades →From SEC Forms 4 and 5. Open-market purchases and sales are highlighted; grants, option exercises and shares withheld for tax are routine.
| Date | Company | Transaction | Shares | Price | Value |
|---|---|---|---|---|---|
| May 17, 2024 | Neurocrine Biosciences Inc. | Option exercise | +2,100 | — | — |
| May 14, 2024 | Neurocrine Biosciences Inc. | Option exercise | +12,500 | $42.76 | $534,500 |
| May 14, 2024 | Neurocrine Biosciences Inc. | Open-market sale | −12,500 | $135.63 | $1,695,375 |
| May 8, 2024 | Travere Therapeutics Inc. | Grant or award | +6,500 | — | — |
| Dec 22, 2023 | Neurocrine Biosciences Inc. | Open-market sale | −10,000 | $130.04 | $1,300,400 |
| Dec 1, 2023 | Neurocrine Biosciences Inc. | Option exercise | +5,000 | $12.98 | $64,900 |
| Dec 1, 2023 | Neurocrine Biosciences Inc. | Open-market sale | −5,000 | $116.77 | $583,850 |
| Sep 12, 2023 | Neurocrine Biosciences Inc. | Option exercise | +5,000 | $12.98 | $64,900 |
| Sep 12, 2023 | Neurocrine Biosciences Inc. | Open-market sale | −5,000 | $115.02 | $575,100 |
| Sep 1, 2023 | Neurocrine Biosciences Inc. | Option exercise | +5,000 | $12.98 | $64,900 |
| Sep 1, 2023 | Neurocrine Biosciences Inc. | Open-market sale | −5,000 | $110.06 | $550,300 |
| May 26, 2023 | Rigel Pharmaceuticals Inc. | Grant or award | +25,000 | — | — |
| May 17, 2023 | Travere Therapeutics Inc. | Grant or award | +4,500 | — | — |
Reviews (0)
Sign in to write a review.
No reviews yet. Be the first to write one.